Marc Frahm

Stock Analyst at TD Cowen

(0.33)

# 4,422

Out of 5,182 analysts

17

Total ratings

23.08%

Success rate

-19.09%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Marc Frahm

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	TBPH Theravance Biopharma	Maintains: Hold	$13 → $15	$16.35	-8.26%	4	Mar 23, 2026
	NKTR Nektar Therapeutics	Initiates: Buy	n/a	$77.50	-	1	Mar 17, 2026
	INCY Incyte	Maintains: Buy	$101 → $128	$96.07	+33.24%	4	Jan 13, 2026
	SANA Sana Biotechnology	Upgrades: Buy	n/a	$3.09	-	2	Jan 8, 2025
	CGEM Cullinan Therapeutics	Initiates: Outperform	n/a	$14.54	-	1	Jun 15, 2023
	XLO Xilio Therapeutics	Initiates: Outperform	n/a	$8.51	-	1	Nov 16, 2021
	NUVL Nuvalent	Initiates: Outperform	n/a	$102.74	-	1	Aug 23, 2021
	JANX Janux Therapeutics	Initiates: Outperform	n/a	$14.93	-	1	Jul 6, 2021
	DAWN Day One Biopharmaceuticals	Initiates: Outperform	n/a	$21.47	-	1	Jun 21, 2021
	BDTX Black Diamond Therapeutics	Initiates: Outperform	n/a	$2.56	-	1	Feb 24, 2020

Theravance Biopharma

Mar 23, 2026

Maintains: Hold

Price Target: $13 → $15

Current: $16.35

Upside: -8.26%

Nektar Therapeutics

Mar 17, 2026

Initiates: Buy

Price Target: n/a

Current: $77.50

Upside: -

Incyte

Jan 13, 2026

Maintains: Buy

Price Target: $101 → $128

Current: $96.07

Upside: +33.24%

Sana Biotechnology

Jan 8, 2025

Upgrades: Buy

Price Target: n/a

Current: $3.09

Upside: -

Cullinan Therapeutics

Jun 15, 2023

Initiates: Outperform

Price Target: n/a

Current: $14.54

Upside: -

Xilio Therapeutics

Nov 16, 2021

Initiates: Outperform

Price Target: n/a

Current: $8.51

Upside: -

Nuvalent

Aug 23, 2021

Initiates: Outperform

Price Target: n/a

Current: $102.74

Upside: -

Janux Therapeutics

Jul 6, 2021

Initiates: Outperform

Price Target: n/a

Current: $14.93

Upside: -

Day One Biopharmaceuticals

Jun 21, 2021

Initiates: Outperform

Price Target: n/a

Current: $21.47

Upside: -

Black Diamond Therapeutics

Feb 24, 2020

Initiates: Outperform

Price Target: n/a

Current: $2.56

Upside: -